Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads

• Manu Anantpadma,
• Thomas Lane,
• Kimberley M. Zorn,
• Mary A. Lingerfelt,
• Alex M. Clark,
• Joel S. Freundlich,
• Robert A. Davey,
• Peter B. Madrid,
• Sean Ekins

Affiliations

Manu Anantpadma

Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, Texas, United States

Thomas Lane

Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, United States

Kimberley M. Zorn

Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, United States

Mary A. Lingerfelt

Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, United States

Alex M. Clark

Molecular Materials Informatics, Inc., Montreal, Quebec, Canada

Joel S. Freundlich

Departments of Pharmacology, Physiology, and Neuroscience & Medicine, Center for Emerging and Reemerging Pathogens, Rutgers UniversityNew Jersey Medical School, Newark, New Jersey, United States

Robert A. Davey

Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, Texas, United States

Peter B. Madrid

SRI International, Menlo Park, California, United States

Sean Ekins

Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina, United States